1. Describe visual outcomes of PPV and the effect of initial polyp location on visual outcomes of PPV for PCV-associated VH, based on a retrospective record review. 2. Identify factors triggering the development of breakthrough VH in patients with PCV and other factors affecting visual outcomes after PPV. 3. Distinguish potential advantages and complications of PPV for PCV-associated VH.
Introduction
Polypoidal choroidal vasculopathy (PCV) is characterized by orange-reddish polypoidal lesions beneath the retinal pigment epithelium (RPE) that usually lead to recurrent serous leakage and haemorrhage. 1 PCV was previously described as 'posterior uveal bleeding syndrome' 2 and 'multiple recurrent retinal pigment epithelial detachments in black women' 3 more than two decades ago. The representative findings, indicated by indocyanine green angiography (ICG), are branching choroidal networks with terminal polypoidal dilatation of the choroidal vessels. 4 PCV is more commonly found in Asian populations. 5 However, the pathogenesis of PCV is still not fully understood. PCV lesions tend to bleed easily, with a rate of 30-63.6% for subretinal haemorrhage 6-8 and 4.5-19.9% for vitreous haemorrhage (VH). 7, 8 In the clinical course of PCV, haemorrhage is usually acute, and visual acuity declines abruptly. Visual prognosis may be limited, with prolonged dense haemorrhages under the RPE or recurrent haemorrhages that lead to RPE and outer retina degeneration. Chan et al 9 proposed a classification based on the clinical patterns at presentation, and each subgroup may have a different natural course or clinical outcome. The massive haemorrhagic group (group 4) was defined as a large subretinal or sub-RPE haemorrhage 42 Macular Photocoagulation Study disc areas in the macular region. In addition, breakthrough VH may also be encountered after treatments such as intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents, 10 photodynamic therapy (PDT), 11, 12 and pneumatic displacements. 13 The visual prognosis of PCV with VH is variable and is generally considered to be poor. 10, 12 However, in a case series reported by Jung et al, 14 the visual outcome of vitrectomy for VH associated with PCV seemed to be better than that of the age-related macular degeneration (AMD) group. As there are few reports evaluating the outcomes of surgery for PCV-related VH, 14, 15 we aimed to evaluate the long-term visual outcomes of PCV with breakthrough VH managed by early pars plana vitrectomy (PPV).
Materials and methods
We conducted a retrospective study of patients with PCV-related breakthrough VH undergoing PPV from August 2008 to March 2012 in the Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan. This study was approved by the Institutional Review Board of National Taiwan University Hospital, Taipei, Taiwan. The study complied with the guidelines of the Declaration of Helsinki. The collected preoperative and postoperative records included a complete medical and ophthalmic history, best-corrected visual acuity (BCVA) with Snellen chart, intraocular pressure, slit lamp examination, dilated fundus examination, optical coherence tomography, fundus fluorescein angiography (FFA), ICG, preoperative treatments, and operation records. Diagnoses of PCV were made preoperatively or postoperatively, based on the results of fundus examination, FFA, and ICG. A branching vascular network with polypoidal structures dilatation demonstrated by ICG was crucial for the confirmation of PCV. The locations of polypoidal lesions were classified into subfoveal, juxtafoveal (within 200 mm of the fovea), and extrafoveal. 16 All patients underwent a standard 20-G system threeport PPV without subretinal manipulation. All operations were performed by a single retina surgeon (CH Yang). The intravitreal injection of bevacizumab was performed at the end of surgery if there was a fresh subretinal haemorrhage, serous retinal detachment (RD), serous RPE detachment, or cystoid macular oedema noted during operation. When an active PCV lesion with recurrent bleeding or leakage was found during the course of postoperative follow-up, an intravitreal bevacizumab injection was performed.
The main outcome measures were BCVA and fundus findings at 3 months postoperatively and at the final follow-up visit. Visual acuity values were converted into the logarithm of the minimal angle of resolution (LogMAR) for statistical analysis. Counting fingers (CFs) was converted to LogMAR 2.0, and hand motion (HM) was converted to LogMAR 3.0. 17 Factors that might influence the visual outcome, including age, gender, presence of systemic disease, size of subretinal haemorrhage, duration of subretinal haemorrhage, duration of VH, location of polypoidal lesions, preoperative treatment with intravitreal bevacizumab injection, or PDT, were evaluated for correlation with the final functional outcomes by a logistic regression test. Fisher's exact test was used to analyse categorical variables. Statistical analyses were conducted using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). Po0.05 was considered to be statistically significant.
Results
Seventeen eyes of 17 consecutive patients (9 men and 8 women) were included in this study. All cases were followed up for at least 6 months. The basic characteristics of these patients were summarized in Table 1 . The mean age of the patients was 60.1 ± 8.5 years (ranging from 45 to 81 years). The mean postoperative follow-up period was 25.18±20.23 months (ranged from 6 to 72 months). Six patients had hypertension, three patients had diabetes mellitus, and one patient was under anticoagulant use. Three patients (17.6%) had PCV lesions in both eyes.
Among these eyes with PCV-related VH, VH was the initial presentation in two eyes, and seven eyes developed spontaneous breakthrough VH during the follow-up period. Four eyes received intravitreal bevacizumab injections, and three eyes underwent PDT before the occurrence of breakthrough VH. The one remaining eye received pneumatic displacement for the subretinal haemorrhage, but RD and VH occurred 10 days later. The average duration from subretinal haemorrhage to VH was 3.5 ± 1.2 weeks (ranging from 2 to 6 weeks). All of the eyes had massive subretinal haemorrhages (the mean subretinal haemorrhage area was 16.7±7.1 in disc size).
Patients underwent PPV 1.3±0.7 months (ranging from 0.1 to 2.5 months) after the onset of the VH. Bevacizumab was injected intravitreally into nine eyes during the operation. The eye with RD and VH after pneumatic displacement received PPV and gas tamponade, and the retina attached postoperatively. No eye developed any complication after PPV, except for cataracts. There was no recurrent VH during the postoperative follow-up. Active PCV lesions were found in five eyes, and bevacizumab was injected. One eye (patient no. 8) developed new PCV lesion with small subretinal haemorrhage at 1 year after vitrectomy. Bevacizumab was injected two times. The haemorrhage resolved and final BCVA was 20/100 (LogMAR 0.7).
Baseline visual acuity was LogMAR 0.95±0.60 before VH (measured at the time of subretinal haemorrhage) . Massive subretinal haemorrhage was noted. ICG revealed polypoidal lesions at the juxtafoveal area. Bevacizumab was injected intravitreally. Visual acuity declined suddenly to CF 2 days after the injection. A VH was discovered, and ultrasonography uncovered marked opacities in the vitreous and beneath the retina. PPV was performed 3 weeks after VH. The improvement of visual acuity was limited by extensive scarring, and VA decreased to HM at final visit (20 months postoperatively).
Discussion
PCV usually presents with recurrent serous and haemorrhagic detachments of the RPE, and massive haemorrhage occurs occasionally with sudden deterioration of vision. 18, 19 The cluster type of PCV lesions, which was the most common formation of the PCV lesions, was found to be related to increased frequency of massive haemorrhage with poorer visual outcomes. 7, 16 Larger PCV size (lesion Z1 disc area) is associated with severe vision-threatening complications, such as suprachoroidal haemorrhage and VH. 20 In some genotype-phenotype analysing studies, the risk genotypes of LOC387715 rs10490924 were correlated with larger lesion size, greater chance of VH, and worse therapeutic response. [21] [22] [23] VH associated with PCV can occur as the initial presentation or during the follow-up period. 14, 15, 24, 25 In this current study, VH was the initial presentation in two eyes, whereas seven eyes were found to have spontaneous breakthrough VH from subretinal haemorrhage during the follow-up period. Ultrasonography was crucial in the setting of VH obscuring fundus detail and helped to exclude more urgent aetiologies. In a study describing the ultrasonographic features of PCV with VH, two characteristic types of ultrasonographic findings were reported that might represent the different stages of the haemorrhagic retinal elevations. 15 The most important sign was the detection of hypoechoic opacities on both sides of a hyper-reflective membrane (Figure 2 , top right and Figure 3 , bottom left), indicating haemorrhages distributed both in the vitreous cavity and in the subretinal space. In contrast, the area under the retinal membrane would be echo free in rhegmatogenous RD. The other ultrasonographic feature of the PCV lesion depicted a dome-shaped elevation with hypoechoes inside and even a fluid level, representing haemorrhagic pigment epithelial detachment. 15 Ultrasonography could also help to exclude other possible causes of VH, such as intraocular tumours or posterior vitreous detachment.
PCV-related breakthrough VH can also develop after manipulations, such as PDT, 11, 12, 26 intravitreal injection of anti-VEGF agents, 10 pneumatic displacement, 13 or combined therapy with PDT and anti-VEGF agents. [27] [28] [29] In the current study, three cases of VH developed after PDT. Four eyes received intravitreal bevacizumab injections, and one eye had pneumatic displacement before the onset of breakthrough VH. Postoperative bleeding is a known complication of PDT for PCV 11, 12 that results in subretinal haemorrhage in 31% of treated eyes and VH in 6.6-12.5% of treated eyes. 12, 26 The risk of massive VH after PDT was higher in PCV than in common AMD, and VH was indicative of poor visual prognosis. 12 Larger laser irradiation spot size (especially 43500 mm) of PDT was considered to be a higher risk for postoperative VH. 12 Three cases in the current study received PDT in eyes with pre-existing subretinal haemorrhages and developed VH 1-6 weeks after the Eye therapy. The laser spot sizes used in this study were 1500, 3500, and 5000 mm, respectively. The mechanism of haemorrhage might be related to the direct effects of laser exposure or to altered choroidal blood flow. 12 PDT would cause occlusion of both the abnormal and physiologic choroidal vessels within the treated area, resulting in increased blood flow in fragile vasculatures and leading to massive haemorrhage complications. 12 Although it is controversial whether combination of intravitreal injection of anti-VEGF agents with PDT could decrease the risk of haemorrhage complication after PDT, [26] [27] [28] [29] intravitreal injection of anti-VEGF agents alone could also induce haemorrhage. Cho et al 10 retrospectively reviewed 54 patients with PCV who had received intravitreal ranibizumab injection. They found postoperative subretinal haemorrhages in five (8.9%) eyes and VH in one (1.8%) eye. All subretinal haemorrhages developed within 1 week after injection. Those with large PCV lesions (size Z15 mm 2 ) carried a higher risk for bleeding. Visual acuity decreased significantly in the eye with postoperative VH. The mechanism of haemorrhagic complications after the intravitreal ranibizumab injection could be an RPE tear, 30 resulting from the contraction of choroidal vessels or changes in choroidal blood flow following ranibizumab injection. 10 In the current study, VH occurred 1 to 4 days following the intravitreal bevacizumab injection in the eyes with pre-existing subretinal haemorrhage, suggesting that intravitreal injection might be a trigger factor for breakthrough VH. It could be postulated that intravitreal injection might cause intraocular pressure fluctuations within short durations of time and stretch of choroid and sclera in the eyes with a massive subretinal haemorrhage that might lead to breakthrough VH. Wu and co-workers 13 retrospectively evaluated 120 eyes that had undergone intravitreal tissue plasminogen activators and pneumatic displacements for submacular haemorrhages. Eighteen eyes (15%) reported complications with breakthrough VH, and two cases (1.67%) suffered from RD. They found a large area of submacular haemorrhage (Z10 disc areas) and PCV as the underlying aetiology were associated with a higher risk of VH after the procedure, and the occurrence of VH did not affect the visual prognosis of submacular haemorrhage. There was only one eye that received pneumatic displacement in our study, and RD accompanied with VH was found 10 days after the procedure. Although PPV and gas tamponade had anatomically successful results, the final VA was restricted by macular scarring and recurrent subretinal haemorrhage.
In the current study, VH occurred 2-6 weeks (3.5 weeks on average) after subretinal haemorrhage, which concurs with the observations of previous studies. 14, 31 Further, all of the eyes in this study had massive subretinal haemorrhages (average haemorrhage area: 16.7 disc size), which suggests that eyes with massive subretinal haemorrhages were at risk of breakthrough VH. Several common characteristics of breakthrough VH recognized in earlier reports, as well as in this study, helped to clarify the mechanism of spontaneous breakthrough VH. VH usually developed several weeks following subretinal haemorrhage, and turbid, thick, organized haemorrhages were seen even in newly developed VH. 14 No breaks could be identified in such cases. Lincoff et al 32 demonstrated in a rabbit model that subretinal blood could cause necrosis of the overlying retina, except for the internal limiting membrane and that fragments of erythrocytes could migrate across the damaged retina into the vitreous cavity. Manipulations such as intravitreal injection of anti-VEGF agents, PDT, and pneumatic displacement may trigger the migration of the subretinal blood that clouds the vitreous. [10] [11] [12] [13] 26 Few studies have reported the visual outcomes of PPV for PCV with breakthrough VH (Table 2) . 10 3 ) was 47.1%, slightly lower than the results (54-60%) of previous studies. 14, 15 A longer follow-up duration with a higher rate of 14 reported recurrent VH after PPV in four cases, which absorbed spontaneously in three eyes. Two eyes developed new PCV lesions within 1 year and was managed by laser photocoagulation in Jalali et al's study. 15 In the present study, there was no recurrent VH during the postoperative follow-up. New PCV lesion with small subretinal haemorrhage occurred in one eye at 1 year after PPV and was treated successfully with intravitreal bevacizumab injection. Long-term follow-up is necessary in cases with PCV-related breakthrough VH to recognize and manage the recurrent lesions earlier.
Several reports studying vitrectomy for AMD-related VH demonstrated poor functional outcomes, possibly due to severe inflammatory reactions, extensions of pre-existing subretinal haemorrhages, and surgical complications. [33] [34] [35] However, our study and other studies 14, 15 reported more favourable visual outcomes of vitrectomy for PCV-related VH. Visual recovery was limited mainly by macular pathology, such as macular scarring, atrophy, or RPE changes. Subretinal blood can act as a barrier to block metabolic exchange, causing degenerative changes of the RPE and outer retina. 36 In this study, none of the following were shown to be related to visual outcomes: age, gender, subretinal haemorrhage size, duration from subretinal haemorrhage to VH, duration from VH to PPV, preoperative treatment with intravitreal bevacizumab injection, or PDT. Cases with systemic disease (DM or HTN) showed a borderline relationship (Fisher's exact test, P ¼ 0.05) with poorer visual outcomes. Eyes with initial polyps at the extrafoveal area had better visual outcomes than those with polyps at the subfoveal or juxtafoveal areas. Foveal microstructures were more likely to be destroyed, as the polyps close to the fovea restricted visual recovery. In a recent study comparing the long-term results of PDT with or without intravitreal bevacizumab injection for PCV, the polyp location was more significantly associated with the final visual improvement rather than treatment modality itself. 37 The limitations of this study include its retrospective study design, small case numbers, and potential confounding factors. Nevertheless, our study has the largest sample size and the longest follow-up duration compared with other studies. These results still provide valuable information for clinical practice.
In summary, the visual prognosis in eyes with PCV-related breakthrough VH is variable after vitrectomy. Massive subretinal haemorrhage is at risk for breakthrough VH. Some treatment modalities, such as intravitreal injection, pneumatic displacement, and PDT, may trigger the development of breakthrough VH. Visual recovery after PPV may be limited by macular pathology, and initial polyps at the subfoveal or juxtafoveal areas may be linked to a poorer functional prognosis. Further prospective study is required for better understanding of the surgical outcomes of PCV-related breakthrough VH. American Medical Association's Physician's Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please refer to http://www. ama-assn.org/ama/pub/about-ama/awards/ama-physiciansrecognition-award.page. The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Creditst. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activites. If you are not licensed in the US, please complete the questions online, print the AMA PRA CME credit certificate and present it to your national medical association for review.
1.
Your patient is a 68-year-old man with polypoid choroidal vasculopathy (PCV)-associated vitreous haemorrhage (VH). According to the retrospective record review by Dr Yang and colleagues, which of the following statements about visual outcomes of pars plana vitrectomy (PPV) for PCV-associated VH is correct? 
